-

04:40:33 PM

REGN Stock News

REGN - Regeneron Pharmaceuticals, Inc.

05/21/21 11:45 AM

Nasdaq : REGN

Teen Scientists and Engineers Win $5 Million at Largest Global High School STEM Competition

$75,000 Top Award Goes to 16-year-old Michelle Hua for Novel Human Action Recognition Algorithm in Regeneron International Science and Engineering Fair 2021Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the

RHEA-AI

positive

05/19/21 5:00 PM

Nasdaq : REGN

clinical trial

Libtayo® (cemiplimab-rwlc) Presentations at ASCO Highlight Expanding Clinical Data in Diverse Cancers

Presentations include first positive clinical data for the fianlimab (LAG-3 inhibitor) and Libtayo combination in advanced melanomaRegeneron will host an investor webcast on Monday, June 7 to provide further updates across its oncology

RHEA-AI

neutral

05/17/21 10:01 AM

Nasdaq : REGN

clinical trialcovid-19

Phase 3 Data Presented at ATS 2021 Show REGEN-COV™ (casirivimab with imdevimab) Reduced Risk of Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

Patients treated with REGEN-COV had 4-day shorter duration of symptoms and significantly reduced viral load compared to placeboSimilar efficacy observed with both doses (1,200 mg and 2,400 mg); U.S. FDA is currently reviewing request to add lower 1,200

RHEA-AI

neutral

05/17/21 9:59 AM

Nasdaq : REGN

Pivotal Data at ATS 2021 Show Dupixent® (dupilumab) Significantly Reduced Asthma Attacks and Improved Lung Function in Children

Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years with uncontrolled moderate-to-severe asthma in a randomized Phase 3 trial, with potential to be best-in-class treatment for these patientsFDA

RHEA-AI

neutral

05/12/21 1:30 PM

Nasdaq : REGN

clinical trial

Positive Phase 3 Libtayo® (cemiplimab) Results in Advanced Cervical Cancer Presented at ESMO Virtual Plenary

Libtayo is the first immunotherapy to demonstrate an improvement in overall survival in advanced cervical cancer, as well as progression-free survival and objective response rate, compared to chemotherapyImprovements in overall survival were

RHEA-AI

neutral

05/06/21 6:30 AM

Nasdaq : REGN

Regeneron Reports First Quarter 2021 Financial and Operating Results

First quarter 2021 revenues increased 38% to $2.53 billion versus first quarter 2020; revenues excluding REGEN-COV TM(1) increased 20% First quarter 2021 EYLEA ® U.S. net sales increased 15% to $1.35 billion versus first quarter 2020 First quarter 2021

RHEA-AI

positive

05/03/21 8:00 AM

Nasdaq : REGN

ATS 2021 Breaking News Session to Feature Pivotal Data on REGEN-COV™ (casirivimab with imdevimab) and Dupixent® (dupilumab)

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that positive Phase 3 data from trials evaluating two Regeneron medicines will be featured at the 2021 American Thoracic Society International Conference (ATS 2021) in the Breaking News:

RHEA-AI

neutral

04/23/21 4:05 PM

Nasdaq : REGN

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:Bank of America Securities Virtual Health Care Conference at 1:15 p.m. ET on Tuesday, May 11, 2021 RBC Capital Markets Virtual Global Healthcare

RHEA-AI

neutral

04/23/21 9:59 AM

Nasdaq : REGN

New Dupixent® (dupilumab) Analyses at Two Upcoming Dermatology Congresses Reinforce Long-term Safety and Efficacy Profile in Patients with Atopic Dermatitis as Young as 6 Years

Nearly 30 data presentations at AAD and ESPD highlight the impact of Dupixent on disease measures including rapid itch relief and sustained improvement in disease severity, as well as quality of life in clinical and real-world settingsRegeneron

RHEA-AI

neutral

04/12/21 1:15 AM

Nasdaq : REGN

clinical trialcovid-19

Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19

Second Phase 3 trial undertaken in collaboration with NIAID to announce results today, both using subcutaneous administration of REGEN-COV in asymptomatic individuals without prior COVID-19 infectionRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

RHEA-AI

neutral

Prev 5 6 7 8 9 10 11 12 13 14 Next

REGN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.regeneron.com
CeoLeonard Schleifer
Security nameRegeneron Pharmaceuticals, Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees9123
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address777 Old Saw Mill River Rd
StateNew York
CityTarrytown
Zip10591-6717
CountryUnited States
Phone19148477000

About Regeneron Pharmaceuticals, Inc.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.